{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:51:14Z","timestamp":1776883874985,"version":"3.51.2"},"reference-count":51,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma GmbH, N\u00fcrnberg, Germany","award":["nr 2016-005"],"award-info":[{"award-number":["nr 2016-005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Age-related macular degeneration (AMD) is a multifactorial disorder, and there is growing evidence of immunological involvement in its pathogenesis. To address this, we aimed to identify biomarker candidates related to retinal antigens in patients with neovascular AMD treated with ranibizumab and healthy subjects. Materials and Methods: This study was designed as a prospective, open, parallel-group, interventional, single-center phase IV trial. Fifty subjects with neovascular AMD and twenty healthy volunteers were enrolled. The primary objective was to assess the efficacy of intravitreally (IVT) administered ranibizumab in terms of the change in best-corrected visual acuity in subjects with all subtypes of neovascular AMD and in a subgroup of pretreated AMD subjects. A secondary objective was to assess the efficacy of the same in terms of the change in central retinal thickness (CRT) in the same subjects. Another secondary objective was to identify antibodies against retinal antigens in patients with neovascular AMD treated with ranibizumab and healthy subjects. The last secondary objective was to correlate functional and structural parameters with the identified biomarker candidates to differentiate between initial and deferred responders to IVT administered ranibizumab. Serum was analyzed using customized antigen microarrays containing 58 antigens. Results: After 12 weeks of ranibizumab treatment, treated patients gained 4.02 letters on average. The central retinal thickness (CRT) measured in the complete AMD study population was significantly (p &lt; 0.001) decreased at Week 24 compared to the baseline measurement, and the mean CRT dropped from 393.4 to 296.8 \u00b5m. A significant increase in the following autoantibodies was detected between the control group and AMD group at Week 24, as well as in the AMD group between baseline and Week 24: antibodies targeting the proteins serotransferrin, opioid growth factor receptor, 60 kDa chaperonin 2, neurotrophin-4, dermcidin, clusterin and vascular endothelial growth factor. Conclusions: The present trial was able to confirm the efficacy of ranibizumab treatment in neovascular AMD, and treatment-na\u00efve patients benefitted the most. Up- and downregulations of antibodies were observed over the course of treatment with ranibizumab. Some antibodies seemed to have a fair correlation with the classification of initial and deferred responders.<\/jats:p>","DOI":"10.3390\/jcm13237033","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:24:51Z","timestamp":1732191891000},"page":"7033","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation of Functional and Structural Outcomes with Serum Antibody Profiles in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7572-4749","authenticated-orcid":false,"given":"Christina A.","family":"Korb","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gerstenberger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-7396","authenticated-orcid":false,"given":"Katrin","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-1635","authenticated-orcid":false,"given":"Katharina","family":"Bell","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW 2050, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Scheller","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"},{"name":"Interdisciplinary Center Clinical Trials Mainz, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-2020","authenticated-orcid":false,"given":"Vanessa M.","family":"Beutgen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolters","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz H.","family":"Grus","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131 Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(82)92679-4","article-title":"Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis","volume":"2","author":"Dumonde","year":"1982","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archopht.118.11.1525","article-title":"Autoimmune retinopathy: Patients with antirecoverin immunoreactivity and panretinal degeneration","volume":"118","author":"Heckenlively","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Adamus, G., Ren, G., and Weleber, R.G. (2004). Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol., 4.","DOI":"10.1186\/1471-2415-4-5"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.clim.2019.108317","article-title":"Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy","volume":"210","author":"Adamus","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI112672","article-title":"Antibodies to neurofilament protein in retinitis pigmentosa","volume":"78","author":"Galbraith","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41433-020-01241-y","article-title":"Anti-retinal autoantibodies in myopic macular degeneration: A pilot study","volume":"35","author":"Sim","year":"2021","journal-title":"Eye"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00920033","article-title":"Autoantibodies to retinal astrocytes associated with age-related macular degeneration","volume":"228","author":"Penfold","year":"1990","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0161-6420(91)32252-8","article-title":"Antiretinal antibodies in serum of patients with age-related macular degeneration","volume":"98","author":"Gurne","year":"1991","journal-title":"Ophthalmology"},{"key":"ref_10","first-page":"113","article-title":"An immunologic study on age-related macular degeneration","volume":"9","author":"Chen","year":"1993","journal-title":"Yan Ke Xue Bao"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1442-9071.2006.01281.x","article-title":"Retinal autoantibody profile in early age-related macular degeneration: Preliminary findings from the Blue Mountains Eye Study","volume":"34","author":"Cherepanoff","year":"2006","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Adamus, G., Chew, E.Y., Ferris, F.L., and Klein, M.L. (2014). Prevalence of anti-retinal autoantibodies in different stages of Age-related macular degeneration. BMC Ophthalmol., 14.","DOI":"10.1186\/1471-2415-14-154"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yexmp.2012.03.007","article-title":"Identification of anti-retinal antibodies in patients with age-related macular degeneration","volume":"93","author":"Morohoshi","year":"2012","journal-title":"Exp. Mol. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Iannaccone, A., Giorgianni, F., New, D.D., Hollingsworth, T.J., Umfress, A., Alhatem, A.H., Neeli, I., Lenchik, N.I., Jennings, B.J., and Calzada, J.I. (2015). Circulating Autoantibodies in Age-Related Macular Degeneration Recognize Human Macular Tissue Antigens Implicated in Autophagy, Immunomodulation, and Protection from Oxidative Stress and Apoptosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145323"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00417-006-0429-9","article-title":"Analysis of IgG antibody patterns against retinal antigens and antibodies to \u03b1-crystallin, GFAP, and \u03b1-enolase in sera of patients with \u201cwet\u201d age-related macular degeneration","volume":"245","author":"Joachim","year":"2007","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Korb, C.A., Beck, S., Wolters, D., Lorenz, K., Pfeiffer, N., and Grus, F.H. (2023). Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041590"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clae.2005.06.004","article-title":"Effects of multipurpose contact lens solutions on the protein composition of the tear film","volume":"28","author":"Grus","year":"2005","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Photocoagulation for Diabetic Macular Edema (1985). Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch. Ophthalmol., 103, 1796\u20131806.","DOI":"10.1001\/archopht.1985.01050120030015"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjophthalmol-2015-306987","article-title":"A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration","volume":"100","author":"Eck","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wecker, T., Grundel, B., Reichl, S., Stech, M., Lange, C., Agostini, H., B\u00f6hringer, D., and Stahl, A. (2019). Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-38934-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502747","article-title":"Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset","volume":"243","author":"Mones","year":"2020","journal-title":"Ophthalmologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1167\/iovs.05-1135","article-title":"The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration","volume":"47","author":"Chowers","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.18388\/abp.2014_843","article-title":"Transferrin receptor levels and polymorphism of its gene in age-related macular degeneration","volume":"62","author":"Wysokinski","year":"2015","journal-title":"Acta Biochim. Pol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: A population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/02713683.2013.848899","article-title":"Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: Effects on serum VEGF concentration","volume":"39","author":"Gu","year":"2014","journal-title":"Curr. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association with Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00417-023-06146-6","article-title":"Analysis of ocular fluid in patients with ranibizumab-recalcitrant neovascular age-related macular degeneration who have serum anti-ranibizumab antibodies","volume":"261","author":"Lee","year":"2023","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study","volume":"124","author":"Heier","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_38","first-page":"64","article-title":"Dysregulation of the OGF-OGFr pathway and associated diabetic complications","volume":"3","author":"McLaughlin","year":"2021","journal-title":"J. Diabetes Clin. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mva.2000.107763b","article-title":"Opioid growth factor modulates angiogenesis","volume":"32","author":"Blebea","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcp.2015.06.016","article-title":"Duration of opioid receptor blockade determines biotherapeutic response","volume":"97","author":"McLaughlin","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1167\/iovs.10-6114","article-title":"Naloxone ameliorates retinal lesions in Ccl2\/Cx3cr1 double-deficient mice via modulation of microglia","volume":"52","author":"Shen","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1167\/iovs.10-5629","article-title":"Opioid receptor activation: Suppression of ischemia\/reperfusion-induced production of TNF-\u03b1 in the retina","volume":"52","author":"Husain","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2011.04.007","article-title":"Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseases","volume":"10","author":"Iaccarino","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"jcs232439","DOI":"10.1242\/jcs.232439","article-title":"Annexin A5 regulates surface \u03b1v\u03b25 integrin for retinal clearance phagocytosis","volume":"132","author":"Yu","year":"2019","journal-title":"J. Cell Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1167\/iovs.08-3019","article-title":"Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells","volume":"51","author":"Lederman","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/02713683.2022.2029904","article-title":"Annexin A1 Promotes Reparative Angiogenesis and Ameliorates Neuronal Injury in Ischemic Retinopathy","volume":"47","author":"Hui","year":"2022","journal-title":"Curr. Eye Res."},{"key":"ref_47","first-page":"949","article-title":"Alpha synuclein gene expression profile in the retina of vertebrates","volume":"13","author":"Angulo","year":"2007","journal-title":"Mol. Vis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100771","DOI":"10.1016\/j.preteyeres.2019.07.004","article-title":"Persistent remodeling and neurodegeneration in late-stage retinal degeneration","volume":"74","author":"Pfeiffer","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12035-019-01735-1","article-title":"Differential Gamma-Synuclein Expression in Acute and Chronic Retinal Ganglion Cell Death in the Retina and Optic Nerve","volume":"57","author":"Liu","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Dias, S.B., de Lemos, L., Sousa, L., Bitoque, D.B., Silva, G.A., Seabra, M.C., and Tenreiro, S. (2023). Age-Related Changes of the Synucleins Profile in the Mouse Retina. Biomolecules, 13.","DOI":"10.3390\/biom13010180"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7033\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:37:02Z","timestamp":1760114222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":51,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237033"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237033","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}